Creative Medical Technology Holdings, Inc. (CELZ) Financial Ratios
20 years of historical data (2006–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↓
0.73
↑+32% vs avg
5yr avg: 0.55
30Y Low0.3·High0.7
ROE
↓
-86.5%
↑-425% vs avg
5yr avg: -16.5%
30Y Low-388%·High188%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
CELZ Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Creative Medical Technology Holdings, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $6M | $5M | $3M | $6M | $4M | $7M | $8M | $465300 | $9M | $2M | $54M |
| Enterprise Value | $-1298708 | $-2537844 | $-2520632 | $3M | $-4155416 | $-3544442 | $9M | $1M | $9M | $2M | $53M |
| P/E Ratio → | -0.91 | — | — | — | — | 0.39 | — | — | — | — | — |
| P/S Ratio | 984.90 | 778.38 | 310.89 | 721.02 | 47.01 | 81.81 | 48.96 | 2.81 | 71.80 | 322.73 | — |
| P/B Ratio | 0.73 | 0.62 | 0.54 | 0.63 | 0.26 | 0.70 | — | — | — | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
CELZ EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | -422.97 | -229.15 | 335.81 | -46.90 | -40.39 | 53.16 | 8.69 | 74.84 | 426.85 | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | -0.15 | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
CELZ Profitability
Margins and return-on-capital ratios measuring operating efficiency
Creative Medical Technology Holdings, Inc. earns an operating margin of -100324.8%. Operating margins have compressed from -62445.9% to -100324.8% over the past 3 years, signaling potential cost pressures or competitive headwinds. A negative ROE of -86.5% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 63.4% | 63.4% | 60.0% | 60.0% | 67.8% | 45.4% | 69.2% | 72.5% | 43.4% | -66.7% | — |
| Operating Margin | -100324.8% | -100324.8% | -52216.9% | -62445.9% | -11562.5% | -3562.2% | -677.7% | -682.9% | -895.7% | -24537.6% | — |
| Net Profit Margin | -99916.8% | -99916.8% | -49940.7% | -58739.7% | -11449.3% | 21892.8% | -22082.2% | -5126.1% | -10977.2% | -55398.1% | — |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -86.5% | -86.5% | -65.8% | -40.3% | -77.8% | 188.0% | — | — | — | — | — |
| ROA | -82.8% | -82.8% | -63.2% | -35.4% | -66.6% | 320.6% | -5818.7% | -1683.3% | -4014.6% | -1011.7% | -474.7% |
| ROIC | -1258.2% | -1258.2% | -118.4% | -58.5% | -218.3% | — | — | — | — | — | — |
| ROCE | -86.8% | -86.8% | -68.8% | -42.9% | -78.6% | -30.6% | — | — | — | — | — |
CELZ Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $7M exceeds total debt of $0, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | — | — | — | — | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.96 | -0.94 | -0.34 | -0.52 | -1.05 | — | — | — | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | — | -0.73 | -0.91 | -0.60 | -0.82 | -3.12 | -119.74 |
Net cash position: cash ($7M) exceeds total debt ($0)
CELZ Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Creative Medical Technology Holdings, Inc.'s current ratio of 25.97x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has declined from 27.65x to 25.97x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 25.97 | 25.97 | 18.73 | 27.65 | 5.64 | 10.22 | 0.00 | 0.01 | 0.07 | 0.01 | 0.49 |
| Quick Ratio | 25.97 | 25.97 | 18.72 | 27.64 | 5.64 | 10.21 | 0.00 | 0.01 | 0.07 | 0.01 | 0.49 |
| Cash Ratio | 25.30 | 25.30 | 18.13 | 26.89 | 5.54 | 10.21 | 0.00 | 0.01 | 0.07 | 0.01 | 0.49 |
| Asset Turnover | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.23 | 0.31 | 0.26 | 0.02 | — |
| Inventory Turnover | — | — | 2.01 | 0.55 | 2.79 | 4.41 | — | — | — | — | — |
| Days Sales Outstanding | — | 3168.44 | — | — | — | 10.34 | — | 12.35 | 28.17 | 365.08 | — |
CELZ Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Creative Medical Technology Holdings, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | 253.8% | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 5.1% | 4.2% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 5.1% | 4.2% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $2M | $1M | $1M | $1M | $324861 | $57946 | $2068 | $1203 | $153 | $140 |
Peer Comparison
Compare CELZ with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 CELZYou | $6M | -0.9 | — | — | 63.4% | -100324.8% | -86.5% | -1258.2% | — |
 MESO | $2B | -17.6 | — | — | 70.2% | -363.1% | -19.0% | -8.5% | — |
 NKTR | $2B | -8.6 | — | — | 100.0% | -236.8% | -217.9% | -57.2% | — |
 RCEL | $128M | -2.4 | 1.9 | — | 82.1% | 89.0% | — | 818.9% | 0.0 |
 VCEL | $2B | 109.8 | 79.8 | 72.3 | 74.4% | 4.0% | 5.1% | 2.5% | 4.4 |
 HALO | $8B | 25.5 | 8.3 | 11.9 | 78.1% | 58.4% | 153.6% | 73.4% | — |
 MDXG | $548M | 11.5 | 5.1 | 7.5 | 82.6% | 15.3% | 21.6% | 42.3% | 0.3 |
 OSUR | $225M | -3.3 | — | — | 41.9% | -59.2% | -18.3% | -20.0% | — |
 ILMN | $21B | 25.5 | 19.6 | 22.6 | 66.7% | 19.9% | 33.4% | 16.8% | 2.3 |
 TECH | $8B | 110.7 | 38.9 | 31.0 | 64.8% | 8.4% | 3.7% | 3.4% | 2.1 |
 CERS | $523M | -31.8 | — | 61.4 | 53.5% | -17.6% | -25.6% | -19.7% | — |
| Healthcare Median | — | 22.3 | 14.5 | 18.5 | 64.0% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 20 years · Updated daily
See CELZ's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs CELZ Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare CELZ vs MESO
Side-by-side business, growth, and profitability comparison vs Mesoblast Limited.
Start ComparisonCELZ — Frequently Asked Questions
Quick answers to the most common questions about buying CELZ stock.
What is Creative Medical Technology Holdings, Inc.'s P/E ratio?
Creative Medical Technology Holdings, Inc.'s current P/E ratio is -0.9x. The historical average is 0.4x.
What is Creative Medical Technology Holdings, Inc.'s ROE?
Creative Medical Technology Holdings, Inc.'s return on equity (ROE) is -86.5%. The historical average is -63.1%.
Is CELZ stock overvalued?
Based on historical data, Creative Medical Technology Holdings, Inc. is trading at a P/E of -0.9x. Compare with industry peers and growth rates for a complete picture.
What are Creative Medical Technology Holdings, Inc.'s profit margins?
Creative Medical Technology Holdings, Inc. has 63.4% gross margin and -100324.8% operating margin.